Arcutis Biotherapeutics Target Price

Arcutis Biotherapeutics's target price stands at $41. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $41 for ARQT implies 49.5% upside versus today's price ($27.53). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Arcutis Biotherapeutics's target price evolved across reporting periods, while the comparison chart places ARQT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Arcutis Biotherapeutics's reading of $41 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.